3 Canadian Small-Cap Stocks to Buy Right Now

Given their favourable growth prospects, I expect these three Canadian small-cap stocks to deliver superior returns.

| More on:

Small-cap stocks have the potential to grow their financials at a high rate compared to mid-cap and large-cap stocks. So, these stocks can deliver superior returns. However, these stocks are highly susceptible to market volatility and are risky. So, investors with higher-risk-taking abilities and a longer investment horizon can invest in these stocks to earn superior returns.


Savaria (TSX:SIS) had reported a solid second-quarter performance yesterday. Its revenue grew 111% to $178.6 million. The acquisition of Handicare and organic growth due to the recovery in economic activities drove the company’s top line. However, unfavourable currency translation offset some of the increases. Meanwhile, the company’s adjusted EBITDA also grew by 89.3% to $27.4 million, supported by strong top-line growth.

Meanwhile, the company’s addressable market is expanding amid a growing aging population and rising income levels. The company’s robust portfolio of products, increasing geographical footprint, and cross-selling opportunities from Handicare’s acquisition could boost its financials in the coming quarters. With its strong financial position, Savaria is well equipped to fund its growth initiatives. It also pays a monthly dividend of $0.04 per share, with its forward yield standing at 2.3%. So, Savaria would be an excellent buy for investors with over three years of an investment horizon.

WELL Health

Second on my list would be WELL Health Technologies (TSX:WELL), which has reported a solid second-quarter performance today. Its revenue grew 484% to $61.8 million, thanks to its acquisition of CRH Medical and strong growth of 432% in its virtual services revenue.

Along with top-line growth, the company’s adjusted EBITDA also rose. For the quarter, the company’s adjusted EBITDA came in at $11.9 million compared to an adjusted loss of $0.5 million in the previous year’s quarter. The accretive acquisition of CRH Medical and higher sales from its virtual services drove its adjusted EBITDA higher. Meanwhile, I expect the uptrend in the company’s financials to continue amid favourable market conditions and its continued acquisitions.

The company has acquired CRH, MyHealth, Intrahealth Systems, ExecHealth, and a 51% stake in Doctors Services Group in the second quarter. With these acquisitions, the company’s management expects its annualized revenue and adjusted EBITDA run rate have reached $400 million and $100 million, respectively. So, I believe the uptrend in WELL Health will continue.


My final pick is Hexo (TSX:HEXO)(NYSE:HEXO), which trades over 66% lower from its January highs. Its weak third-quarter performance and lack of progress in cannabis legalization at the federal level in the U.S. have weighed on its stock price. However, amid increased legalization and rising cannabis usage for medical purposes, the cannabis market is expanding.

Amid the expansion of its addressable market, HEXO is looking to strengthen its competitive positioning by launching new products and raising THC content in its hash category. Its acquisitions could act as significant growth drivers. The company has acquired Zenabis while working on completing 48North Cannabis and Redecan deals.

These acquisitions could significantly expand its product offerings and strengthen its market share in the Canadian recreational cannabis space. Also, the synergies can deliver significant savings, thus improving HEXO’s margins. So, given its healthy growth prospects and a substantial discount on its stock price, I expect HEXO to deliver superior returns.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Tech Stocks

Man considering whether to sell or buy
Tech Stocks

BlackBerry Stock Is Down 20%: Buy the Dip or Call It a Pass?

BlackBerry stock has seen a series of 20% monthly dips since December 2023. Should you buy the dip or call…

Read more »

A shopper makes purchases from an online store.
Tech Stocks

Kinaxis: The AI Stock Investors Are Missing Out On

Kinaxis stock (TSX:KXS) is one AI stock you don't want to miss, with proven results and long-term contracts leading to…

Read more »

telehealth stocks
Tech Stocks

Forget Shopify Stock: 1 Tech Stock to Buy Instead

Shopify stock (TSX:SHOP) plunged by over 20% after earnings guidance for the second quarter came in lower, but this other…

Read more »

data analytics, chart and graph icons with female hands typing on laptop in background
Tech Stocks

Down 27% But Not Out: Why Dye & Durham Is a Buy Today

Dye & Durham stock reported a steep fall of 27% in two months. What happened? Should you be worried about…

Read more »

A chip in a circuit board says "AI"
Tech Stocks

These 2 AI Stocks Are Set to Soar in 2024 and Beyond

Here are two of the best AI stocks in Canada that you can buy now and hold for at least…

Read more »

edit Sale sign, value, discount
Dividend Stocks

2 Bargains I’d Buy as They Dip Toward 52-Week Lows

Buying a stock at its 52-week low is a bargain when you are confident this stock will recover sooner or…

Read more »

stocks rising
Dividend Stocks

2 Market-Beating TSX Stocks That Are Still Buys Today

goeasy (TSX:GSY) stock has easily beaten the TSX. Together with Celestica (TSX:CLS), the growth stocks could gain much more value…

Read more »

Growth from coins
Tech Stocks

A Few Years From Now, You’ll Wish You Had Bought This High-Growth Stock

Are you looking for a high-growth stock that can make you a millionaire a few years from now? Then read…

Read more »